Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Dattoli Cancer Center and Brachytherapy Research Institute Sanofi-Aventis |
---|---|
Information provided by: | Dattoli Cancer Center and Brachytherapy Research Institute |
ClinicalTrials.gov Identifier: | NCT00264017 |
In the past ten years, newer drugs with more selective affinity for the alpha-receptor have been introduced. Alfuzosin (Uroxatral) and Tamulosin(Flomax are two second generation alpha-blockers. In the course of our clinical proctice, both drugs have been used routinely. This retrospective comparison is intended to be a priliminary comparison of their effectiveness and side effects.
Condition |
---|
Prostate Cancer Patients Undergoing External Radiation and Seed Implantation |
Study Type: | Observational |
Study Design: | Longitudinal, Defined Population, Retrospective Study |
Official Title: | Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs Twice Daily Dosing of Flomax-A 3 Month Retrospective Efficacy Analysis |
Ages Eligible for Study: | 45 Years to 80 Years |
Genders Eligible for Study: | Male |
Inclusion Criteria:
Exclusion Criteria:
United States, Florida | |
Dattoli Cancer Center and Brachytherapy Research Institute | |
Sarasota, Florida, United States, 34237 |
Principal Investigator: | Michael J Dattoli, MD | Dattoli Cancer Center and Brachytherapy Research Institute |
Study ID Numbers: | L0087 |
Study First Received: | December 6, 2005 |
Last Updated: | December 6, 2005 |
ClinicalTrials.gov Identifier: | NCT00264017 |
Health Authority: | United States: Institutional Review Board |
Alfuzosin Prostatic Diseases Genital Neoplasms, Male Tamsulosin |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
Neoplasms Neoplasms by Site |